Ampio Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows used in operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation, net of forfeitures
Restricted stock award compensation, forfeitures
Issuance of common stock for services
Depreciation and amortization
Long-lived assets impairment
Right-of-use asset impairment
Loss on sale of fixed assets
Paycheck Protection Program funding that offsets qualified expenses
Paycheck Protection Program loan forgiveness
Net gain from elimination of ARO obligation
Accretion of asset retirement obligation
Derivative gain
Changes in operating assets and liabilities:
Increase in insurance recovery receivable
(Increase) decrease in prepaid expenses and other
Increase (decrease) in accounts payable and accrued expenses
Decrease in lease liability
Proceeds received under the Paycheck Protection Program

Net cash used in operating activities
Cash flows used in investing activities
Net cash used in investing activities
Cash flows used in financing activities
Proceeds from sale of common stock in connection with the equity distribution agreement
Costs related to sale of common stock in connection with the equity distribution agreement
Proceeds from sale of common stock in connection with the "at-the-market" equity offering program
Costs related to sale of common stock in connection with the "at-the-market" equity offering program
Costs related to sale of common stock in connection with the public offering
Proceeds from warrant exercises
Costs related to warrant exercises
Proceeds from option exercises
Other
Proceeds from sale of common stock and warrants in connection with the registered direct offering
Costs related to the sale of common stock and warrants in connection with the registered direct offering
Proceeds from warrant and stock option exercises, net
Funding of tax obligation relative to shares withheld in connection with restricted stock awards

Net cash used in financing activities
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Non-cash transactions:
Commercial insurance premium financing agreement
Initial lease liability arising from the adoption of ASC 842
Initial recognition of right-of-use asset arising from the adoption of ASC 842
Warrant derivative liability in connection with the public offering
Recognition of asset retirement obligation

Comments